基础医学与临床 ›› 2022, Vol. 42 ›› Issue (9): 1433-1437.doi: 10.16352/j.issn.1001-6325.2022.09.1433

• 短篇综述 • 上一篇    下一篇

多巴胺受体激动剂治疗中相关冲动控制障碍的研究进展

张睿, 伍学焱*   

  1. 中国医学科学院 北京协和医学院 北京协和医院 内分泌科 国家卫生健康委员会内分泌重点实验室, 北京 100730
  • 收稿日期:2021-07-12 修回日期:2022-02-24 出版日期:2022-09-05 发布日期:2022-09-02
  • 通讯作者: wsheyan@vip.sina.com
  • 基金资助:
    国家自然科学基金(81771576, 81971375); 北京市自然科学基金(7202151, 7212080)

Progress in the treatment with dopamine receptor agonist-induced impulse control disorders

ZHANG Rui, WU Xue-yan*   

  1. Department of Endocrinology, Key laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China
  • Received:2021-07-12 Revised:2022-02-24 Online:2022-09-05 Published:2022-09-02

摘要: 多巴胺受体激动剂(DA)治疗的高泌乳素血症患者可出现冲动控制障碍(ICD),如病理性赌博、性欲亢进、食欲亢进和强迫购物。这种现象同样可在DA治疗的帕金森病(PD)或其他神经系统疾病患者中出现。发病机制可能是DA过度刺激了D3受体。直接停药是较为公认治疗方法,可得到较好缓解。

关键词: 冲动控制障碍, 多巴胺受体激动剂, 高泌乳素血症

Abstract: It is found that patients with hyperprolactinemia may have impulse control disorder(ICD) when treated with dopamine receptor agonist(DA), such as pathological gambling, high sexual desire, high appetite and forced shopping. This phenomenon also occurs in patients with Parkinson's disease (PD) or other neurological diseases treated with dopamine agonists. The pathogenesis may be that DA overstimulates D3 receptor. Drug withdrawal is a well accepted treatment method, which may reach a better catabatic outcome.

Key words: impulse control disorder, dopamine receptor agonist, hyperprolactinemia

中图分类号: